Swiss pharma giant Novartis (NOVN: VX) has released details from a new analysis of a major study into its heart drug Entresto (sacubitril/valsartan).
The post-hoc analysis of a subgroup of patients with reduced ejection fraction heart failure and diabetes suggested that Entresto can improve glycemic control. New use of insulin was also reduced by 29% among patients taking Entresto, compared to the control group.
Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze